- $594.92m
- $591.86m
- $126.08m
- 62
- 29
- 44
- 41
Annual cashflow statement for SurModics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1.12 | 4.24 | -27.3 | -1.54 | -11.5 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.65 | 6.34 | 7.92 | 7.95 | 8.78 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.11 | -4.86 | -12.3 | -4.24 | -5.36 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 14 | 15.4 | -17.2 | 10.5 | 0.248 |
| Capital Expenditures | -3.67 | -6.28 | -3.37 | -2.92 | -3.49 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -5.39 | -19 | 9.6 | -3.9 | 0.555 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -9.07 | -25.2 | 6.23 | -6.82 | -2.94 |
| Financing Cash Flow Items | -6.26 | -2.9 | -1.62 | -2.51 | -4.17 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4.65 | 10.2 | -0.375 | 18.4 | -2.95 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.424 | 0.368 | -12.2 | 22.4 | -5.3 |